Tuesday, October 15, 2019
Oral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels
  SocialTwist Tell-a-Friend  

BARCELONA, Spain, Sept. 17,  2019 /PRNewswire/ -- Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in HbA1c were demonstrated with 7 mg and 14 mg oral semaglutide vs all comparators including placebo, Jardiance ® (empagliflozin 25 mg), Januvia ® (sitagliptin 100 mg) or Victoza ® (liraglutide 1.8 mg). The results were presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)[1]. Oral semaglutide is an investigational once-daily glucagon-like peptide-1 (GLP-1) analogue in a pill.

In the analysis, data from 5,657 participants in PIONEER 1–5, 7 and 8 were grouped by trial according to baseline HbA1c (≤8.0%, >8.0–≤9.0% and >9.0%). The proportion of people with type 2 diabetes achieving an HbA1c target of <7% was greater with oral semaglutide 7 and 14 mg vs comparators in all trials and across all HbA1c baseline subgroups.

"People with type 2 diabetes have individual treatment goals related to glycaemic control," said Dr Juris Meier, professor of medicine and head of the division of diabetology and GI endocrinology at the St. Josef-Hospital of the Ruhr-University of Bochum, Germany. "The findings from this analysis are particularly meaningful as they show that oral semaglutide improves glycaemic control in a wide spectrum of people with type 2 diabetes."

The safety profile of oral semaglutide across the PIONEER programme was consistent with that of the GLP-1 receptor agonist class and similar to those seen with subcutaneous semaglutide.

"This analysis reinforces the findings seen throughout the PIONEER trial programme, demonstrating oral semaglutide's efficacy in HbA1c reductions compared to commonly used type 2 diabetes treatments," said Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "If approved, oral semaglutide will become the first and only oral GLP-1 receptor agonist with the potential to help people with uncontrolled type 2 diabetes better manage their condition."

About the exploratory analysis and the PIONEER clinical trial programme

The PIONEER 1-5, 7 and 8 trials, included in this analysis, investigated oral semaglutide against diet and exercise (PIONEER 1), empagliflozin 25 mg (PIONEER 2), sitagliptin 100 mg (PIONEER 3 and 7), liraglutide 1.8 mg (PIONEER 4) and as an add-on to insulin (PIONEER 8). PIONEER 5 evaluated oral semaglutide compared to placebo in patients with moderate renal impairment.

The PIONEER phase 3a clinical development programme for oral semaglutide was a global development programme that enrolled 9,543 people with type 2 diabetes across 10 clinical trials.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.


1.  Meier JJ, Bauer R, Blicher TM, et al. Efficacy of oral semaglutide according to baseline HbA1c: an exploratory subgroup analysis of the PIONEER trial programme. 55th Annual Meeting of the European Association for the Study of Diabetes. Barcelona, September 2019.

Further information:

Mette Kruse Danielsen: +45 3079 3883, mkd@novonordisk.com  
Ken Inchausti (US): +1 609 240 9429, kiau@novonordisk.com

Peter Hugreffe Ankersen: +45 3075 9085, phak@novonordisk.com  
Valdemar Borum Svarrer: +45 3079 0301, jvls@novonordisk.com  
Ann Søndermølle Rendbæk: +45 3075 2253, arnd@novonordisk.com  
Kristoffer Due Berg (US): +1 609 235 2989, krdb@novonordisk.com  


More News by PR Newswire India

Medisanté Earns Acclaim from Frost & Sullivan for Ensuring Better Care Outcomes while Reducing Costs

INSIDE INFORMATION: BW LPG Contemplated Sale of Shares

School House Crafts Multi-Sensory Journey of Discovery and Re-collection for La Mer Campaign Exhibition

Vevue Partners with CBX Exchange for Initial Auction Offering

Frost & Sullivan Recognizes Pepco Holdings and Carlsbad Municipal Water District with Excellence in Resourcefulness Awards at Itron Utility Week

His Holiness The Dalai Lama Awarded Honorary Doctorate by Chitkara University

Surplus Keslow Cinematography Gear Up For Auction

Libyan Investment Authority Loses Claim in the UK Court of Appeal - London

Artificial Intelligence for Risk Management Process by MovingNow

Maruti Suzuki Arena Devils Circuit Season 2019-20 Draws Over 6K Runners in Hyderabad

Quectel Achieves Industry's First 5G Data Call over 5G mmWave Module

Artprice by Artmarket: The Gagosian's Grand Projects for the Late Simon HantaĂŻ (1922-2008)

Ryan International Group of Schools Receive India's Most Respected Brand Award 2019

JD Institute Of Fashion Technology, South Announced its New Domain

VeChain Is Leading Co-sponsor of GDST Seafood Trackathons

The World's Largest Automakers, Along with MOBI, Announce a Joint Proof of Concept for the First Vehicle Identity on Blockchain

Indiannica Learning Announces the Launch of Indiannica Quiz League

Third Annual Convocation Ceremony Will be Celebrated in Apex Professional University

An Encounter of Two Icons: Tic Tac® Meets Coca-Cola®

Birlasoft to Accelerate Invacare's Business Transformation Journey Signs US$ 240 mn, Multi-year Deal, to Provide Complete IT-as-a-Service (ITaaS)

Bali Zoo Celebrated Tumpek Kandang Ritual for all its Resident Faunas

Nitin Mantri Becomes ICCO President

DMCC Awarded 'Global Free Zone of the Year' for a Record Fifth Consecutive Year

Apex Professional University Signed MoU with Life Science Sector Skill Development Council

Find TVU Networks at Broadcast India 2019

UAE and UNESCO Renew Partnership, Extending Efforts to Restore Historic Churches in Mosul

Over 70,000 Visitors, SR2m Falcon Sales on First Day of Riyadh Exhibition

The First Huion Tablet of Inspiroy Dial Series, Q620M was Unveiled at Hong Kong Electronics Fair

ZEISS showcases next-level eye care digitalization at AAO 2019

On Your Marks: 2019 Xi'an Yango International Marathon Starts 20 October

Autodesk Fusion 360 Tools Enable Social Hardware to Advance Design of Prosthetics

Bionik Gold Knee- A New Lease of Life for Young Arthritis Patients

Joy Forum19 to boost Saudi entertainment sector

US Navy submarine support ship arrives i...
Most arrested IS sympathisers inspired b...
A very big day for us, says Abhijit Bane...
Intense questioning in Kerala family ser...
5 Punjab cops in jail for militancy-era ...
Delhi police special team arrest crimina...
 Top Stories
Friends turning foes at KCA has bec... 
HFCL launches next-gen WiFi product... 
Four hockey players killed in tragi... 
Odisha govt announces infra support... 
Zimbabwe reinstated as ICC full mem... 
SC to hear CBI plea against Delhi H... 
Indian-origin prof shares Economics... 
Margaret Atwood, Bernardine Evarist...